About CJC-1295 Compound

About This Site

CJC-1295 Compound is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295, the synthetic GHRH analog. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word 'compound' in this site's name is editorial framing — it denotes the site's position as a documentary compendium of the CJC-1295 compound literature, not a claim about services offered. No clinical services, prescriptions, consultations, or products are available here.

The research record we summarize is modest in scope: two randomized, placebo-controlled human trials (Teichman 2006 and Ionescu 2006, combined n=24, maximum 49 days), a pharmacological characterization study in rats (Jetté 2005), rodent models for growth normalization and ipamorelin-specific effects, and the FDA 2024 compounding docket. We document those findings accurately, including the limits of the evidence — small sample sizes, short durations, the absence of human data for the no-DAC form, and the absence of long-term safety data for either form.

Editorial Standards

Every quantitative claim on this site is cited to a peer-reviewed publication or official regulatory document. We do not invent citations; we do not fabricate PMIDs or DOIs. Where a question is asked by researchers and the answer is 'not yet studied in humans,' we write that plainly.

We do not link to vendors, online pharmacies, or other commercial sources of CJC-1295 or any peptide. We do not recommend dosing regimens. We do not advise on medical treatment. The site is an archive of what the studies have measured, rendered in a format that is readable by humans and machines alike.

This site carries no medical, scientific, or governmental endorsement. It is an independently maintained editorial digest.

Regulatory Status